Key result
Pulmonary endarterectomy plus chemotherapy and targeted therapy is linked to prolonged pulmonary artery sarcoma survival.
Why the study?
Pulmonary artery sarcoma is a rare malignancy with poor prognosis and non-specific manifestations that lead to delayed treatment, whereas early diagnosis and radical resection offer potential prolonged survival.
Population
13 patients diagnosed with pulmonary artery sarcoma between 2015 and 2019
Design
Retrospective single-center case series
Authors
Loading...
Supports multimodal therapy in pulmonary artery sarcoma; hypothesis-generating and requires prospective validation before practice change.
Observational (n=13)
No
Tailored diagnostic approaches and a combination of pulmonary endarterectomy, chemotherapy, and targeted therapy may prolong survival in patients with rare pulmonary artery sarcoma.
Zhang et al. (2020) conducted an observational in Pulmonary artery sarcoma (n=13). Pulmonary endarterectomy combined with chemotherapy and targeted therapy was evaluated on Clinical outcome and survival. Pulmonary endarterectomy combined with chemotherapy and targeted therapy prolonged survival in a cohort of 13 patients with pulmonary artery sarcoma, of whom 8 (61.5%) had metastasis at diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: